Introduction 

Primary Lateral Sclerosis (PLS) and Amyotrophic Lateral Sclerosis (ALS) are both progressive neuromuscular disorders with distinct characteristics and implications. Often confused due to their similarities with motor neuron diseases (MNDs), understanding their respective similarities and differences are crucial for accurate diagnosis and appropriate management.

PLS primarily involves the upper motor neurons (UMNs), leading to progressive weakness and spasticity in voluntary muscles throughout the body, usually starting from the lower limbs. Whereas, involving both upper and lower motor neurons (LMNs), ALS usually results in rapid progressive muscle weakness, atrophy, and eventually paralysis. Albeit their varying clinical manifestations, both conditions could significantly impact the quality of life and in need of comprehensive medical care. 

Thereby, this article will delve among the prevalence, pathophysiology, clinical presentations, diagnosis, treatment options, and prognosis for PLS and ALS, highlighting the key distinctions to promote awareness and management of these neurodegenerative diseases.^1,2

Prevalence 

PLS is estimated to affect 1-3 cases per 100,000 individuals in their early 50s, accounting for 5% of MND cases. ALS, with a prevalence of around 4-8 cases per 100,000 individuals at mean age of 54-58, represents 85% of all MND cases^3,4,5

Pathophysiology 

Both PLS and ALS are caused by motor neuron degeneration due to intracellular trafficking, mitochondria and lipid metabolic dysfunctions.^6,7 Though both possess their respective genetic/ familial forms and are mostly sporadic. They exhibit distinct pathophysiological features. 

In PLS, the selective UMNs degeneration among motor cortex (descending corticospinal and corticopontine tracts), in the absence of LMNs involvement is its primary pathology.^3,7,8 Axonal degeneration, reflected upon normal or mildly abnormal electromyography (EMG) results, as well as cortical thinning or atrophy among the precentral gyrus (motor cortex); along with inflammatory mediators released by astrocytic and microglial activation. These degenerations would delay neuronal conductions, hence disrupting signal transmission from the motor cortex to the spinal cord, and subsequently peripheral, voluntary muscles.^6,7

In contrast, ALS affects both UMNs and LMNs, involving neuronal degeneration in the motor, cortex, brainstem, and spinal cord. This leads to more rapid progressive muscle weakness, atrophy, and eventual complete paralysis.⁷ While chronic widespread denervations and reinnervations can be shown among EMG; motor band signs in precentral gyri, hyperintensity and volume loss among the corticospinal tract and internal capsule can also be revealed upon MRI studies.⁹ 

Although the exact causing mechanism is still unclear. While several genetic mutations, such as ALS2 have been discovered in juvenile or familial PLS cases. TDP-43 protein aggregations, SOD-1 mutation, RNA processing abnormalities, and excitotoxicity that disrupt cellular functioning lead to neuronal death has played a significant role among ALS pathology.^6,10

Symptoms 

PLS and ALS are both progressive neurological disorders affecting motor neurons, which exhibit distinct symptoms.^1,2,5

Note: Both PLS and ALS will usually not affect your vision, hearing, taste, smell, touch, and sexual functions. 

Diagnosis and tests 

PLS and ALS are both diagnosed through a ruling-out process, a healthcare provider will only confirm PLS or ALS after a set of physical examination, and some diagnostic testing which includes:^1,2

• Blood and urine test, cerebrospinal fluid analysis through spinal tap 
• Neurological examination for reflexes and other responses 
• Neuroimaging magnetic resonance imaging (MRI) to check for structural abnormalities of your brain and spinal cord 
• Nerve conduction and electromyography (EMG) to measure your muscles' electrical activities and nervous responses on signalling
• Muscle and/or nerve biopsy as tissue sampling for cellular abnormalities microscopic examination 

Diagnostic criteria 

Despite PLS and ALS respective diagnostic criteria, below is a brief general summary. 

Differential diagnosis 

Treatment and management 

PLS and ALS are currently still without a definite cure, despite the FDA-approved drugs for ALS. 

Supportive symptom management has been the main focus for both:^1,2

Medications for symptom relief 

PLS and ALS can both cause pain, muscle stiffness, spasms, cramps due to UMN involvements. Discomforts and distress can be eased by medications prescription:^1,15,16

Physical therapy

Tailored physiotherapy rehabilitation is crucial for both PLS and ALS. For PLS, therapy aims to maintain mobility and manage spasticity. In ALS, it focuses on preserving functional abilities, improving breathing techniques, and maximizing quality of life.¹⁷

Occupational therapy

Customized occupational therapy is essential in supporting PLS and ALS populations for daily functioning and overall well-being. While occupational therapy in PLS focuses on adapting activities, preserving independence, and assistive devices provision. It addresses functional limitations, and recommends adaptive techniques, while assisting with communication and mobility aids.¹⁸

Speech therapy

Speech therapy is instrumental in facilitating communication and swallowing abilities for effective social interactions in both PLS and ALS. While it aims to improve articulation, intelligibility and swallowing in PLS. Among ALS, it focuses on alternative communication methods (i.e. AAC, voice bank), and swallowing interventions to compensate for progressive speech and swallowing impairments.¹⁹

Respiratory therapy

Respiratory therapy is crucial in managing respiratory complications. For PLS, respiratory therapy focuses on maintaining optimal lung function and managing the rarely occurring respiratory symptoms. In ALS, it assists with respiratory muscle weaknesses, providing strategies, devices such as non-invasive ventilation, and mechanical ventilator through tracheosomy eventually, to support breathing and enhance quality of life.²⁰

Others such as nutritionists, social workers and clinical psychologists can also help to maintain your dietary, social and psychological well-being when necessary.

Prognosis 

PLS and ALS are both MNDs with distinct prognoses. 

Primarily affecting UMNs, PLS usually progresses slowly over many years or decades, allowing individuals to have a near-normal lifespan, despite mobility challenges caused by progressive muscle weakness and spasticity.

On the other hand, ALS is a more aggressive disease with a generally poor prognosis. Most individuals will face a progressive voluntary muscle decline, including difficulty with movement, speech, swallowing, and breathing. It might even progress into locked-in syndrome, with the loss of nearly all (except for blinking and minimal eye movements) or all voluntary muscle control. The average life expectancy after an ALS diagnosis ranges from 2-5 years.^1,2,21

However, it is important to consider that the prognosis can vary among individuals based on several factors, such as age, overall health, symptom management, and access to medical care. 

FAQs 

What are some warning signs of PLS or ALS 

• Unexplained persistent and progressive muscle weakness/stiffness 
• Difficulty with coordination, balance, or fine motor skills 
• Slurring speech or difficulty articulating words 
• Swallowing difficulties (choking or frequent coughing when eating/drinking)
• Breathing problems (shortness of breath or noticeable changes in breathing patterns)
• Noticeable muscle wasting or twitching 
• Neurological symptoms that impairs daily functioning

What are some other motor neuron diseases?

• Progressive bulbar palsy (PBP)
• Progressive muscular atrophy (PMA)

Can PLS turn into ALS? 

Early signs of ALS can look like PLS. As most PLS-similar cases are actually UMN-predominant ALS, that eventually develops into ALS. A PLS diagnosis should only be made after symptoms onset for at least 3-4 years.¹

Summary 

Primary lateral sclerosis (PLS) and Amyotrophic lateral sclerosis (ALS) are both motor neuron diseases with distinct features. PLS primarily affects upper motor neurons, causing gradual muscle stiffness and weakness, while ALS involves the impairment of both upper and lower motor neurons, resulting in progressive muscle weakness and atrophy. Due to the symptoms overlap, and common misdiagnoses, comprehensive medical assessment in distinguishing the two is vital for an accurate diagnosis and comprehensive, tailored management. 

Join movements to advance research and care for individuals battling PLS and ALS. Your support can indeed make a profound difference in improving outcomes, offering hope, and ultimately finding a cure for these deliberating neurological conditions.